Clinical trial to assess if mangosteen extract can help treat schizophrenia

By Gary Scattergood contact

- Last updated on GMT

"We aren’t suggesting this is a wonder drug, but we must investigate," says Professor John McGrath.
"We aren’t suggesting this is a wonder drug, but we must investigate," says Professor John McGrath.

Related tags: Clinical trial

Researchers have begun clinical trials to assess if an extract from mangosteen can help treat schizophrenia.

Mangosteen is a tropical evergreen fruit native to Indonesia. The thick purple rind of the fruit contains xanthones, which are often used in herbal teas and traditional medicines.

Queensland Brain Institute​ Professor John McGrath​ is now conducting a trial into the role of mangosteens in easing symptoms of psychosis.

Previous research has indicated that the very potent antioxidants in mangosteen rind might provide a safe and effective treatment, with no side-effects.

“This is a gentle and safe intervention which evidence so far suggests could improve symptoms, and it’s important we investigate its potential as a matter of urgency,” ​Professor McGrath said.

“We aren’t suggesting this is a wonder drug, but we must investigate potential new treatments which are safe, effective and don’t have the current medication’s side-effects like weight gain, which can lead to other major health problems.

“Finding better treatments for schizophrenia is difficult, it will take decades, so let’s start now.”

Citizen scientists

For this trial run through Cadence​, 150 people with schizophrenia will be recruited over the next two years in Brisbane and in Geelong, Victoria with colleagues at Deakin University.

Participants will receive two tablets a day for 24 weeks, then have four weeks’ follow-up. Their symptoms will be closely monitored, to see whether hallucinations, delusions, moods and energy levels are improved.

“When people join a clinical trial like this, they become our citizen scientists, part of our research team.

“That is an inspiring and heart-warming trust which we hope will ultimately lead to better lives for all patients, even if it’s only a modest improvement,”​ Professor McGrath said.

The Cadence trials are funded by Professor McGrath’s National Health and Medical Research Council John Cade Fellowship in Mental Health Research, and by a grant from the Stanley Medical Research Institute​ in the US.

Related news

Related products

show more

Naturally stable astaxanthin for healthy aging

Naturally stable astaxanthin for healthy aging

Lipofoods, a Lubrizol Company | 16-Oct-2020 | Product Presentation

In this video, the Nutraceuticals Division of Lubrizol Life Science Health presents ASTAGILE™ microcapsules, a natural, stable microencapsulated astaxanthin...

A wish come true for the allergy prone

A wish come true for the allergy prone

Indena | 21-Sep-2020 | Technical / White Paper

New research has confirmed that Indena’s Quercefit™ - quercetin Phytosome® - is an effective natural remedy promoting wellbeing in sensitive or intolerant...

cognitaven® boosts cognitive performance

cognitaven® boosts cognitive performance

Anklam Extrakt GmbH | 30-Aug-2020 | Clinical Study

Within the course of a randomised, double-blind, placebo-controlled study, the acute and chronic effects of green oat (Avena sativa) herb extract on cognitive...

Related suppliers

Follow us

Products

View more

Webinars

Nutra Champions Podcast

Nutra Champions Podcast